Abstract: The invention relates to the use of active ingredients, which increase the concentration of pyrimidine-based elements for nucleic acid biosynthesis in the body, in particular to the use of pyrimidine nucleosides and/or prodrugs produced therefrom, for reducing the side-effects of inhibitors of nucleic acid biosynthesis or their precursors, in particular by activating the biosynthesis of mitochondrial DNA (mtDNA). The invention also relates to the use of said active ingredients, in particular pyrimidine nucleosides and/or prodrugs for producing pharmaceutical preparations for reducing the aforementioned side-effects and to combinations or products for administering active ingredients of this type, in particular pyrimidine nucleosides and/or prodrugs produced therefrom, comprising inhibitors of nucleic acid biosynthesis or their precursors.

Abstract: A selenium yeast product for use in food, dietary supplements or drugs containing significant and homogeneous amounts of easily digestible organically bound selenium, in which the content of selenium compounds is in the range of between 1000 and 1600 ppm, and in which product the content of 1-selenomethionine constantly constitutes at least 55% of the total selenium content, and in which product the content of selenium in inorganic selenium compounds does not exced 1% of the total selenium content. Furthermore, a method of preparing a selenium yeast product for use in food, dietary supplements, or drugs whereby said yeast is cultivated on a minimal medium under aerobic conditions, while nutrients are added to the yeast during the cultivation to an extent corresponding to the consumption of said nutrients in the yeast; glucose and/or maltose are the sole sources of carbon in the feeding medium.

Abstract: A pharmaceutical formulation comprising organic or inorganic selenium, .beta.-carotene or vitamin A, ascorbic acid or a salt or ester thereof; .alpha.-tocopherol or a derivative thereof, methionine and coenzyme Q10 together with a pharmaceutically acceptable carrier therefor suitable for treating such diseases as primary biliary cirrhosis.

Abstract: Antioxidative pharmaceutical formulation comprising L-selenomethionine, .beta.-carotene, ascorbic acid (vitamin C), D-.alpha.-tocopherylacetate (vitamin E) and L-methionine together with a pharmaceutically acceptable carrier therefor.